HORIZON BLUE CROSS BLUE SHIELD NEW JERSEY

ONCOLOGY CONDITION MANAGEMENT



Horizon's Global Oncology Strategy



Our vision is to develop a joint approach to oncology care delivery advancing common goals of quality, enhanced patient experience, and lower cost of care.



To do so, Horizon aims to create an oncology ecosystem amongst interested and capable New Jersey cancer care providers fostering ongoing close collaboration with several existing cancer care organizations and advancing closer collaboration with others.



Horizon aims to implement custom oncology strategies with provider partners in the cancer care ecosystem.



Data sharing / integration is required to power precision analytics to find the Value of Precision Medicine in Real World Settings and encourage appropriate use.

Strategic Pillars for Oncology Initiatives

Horizon's Oncology Program initiatives are being designed with the intended goals to (1) reduce ineffective care/unnecessary costs for cancer care, (2) improve coordination of cancer care and patient experience, (3) explore advanced clinical solutions to cancer treatment.

Oncology Care Optimization

Driving optimal care of the active cancer patient

- Value-Based Agreements (Episodes of Care, TME)
- Targeted Site of Care
- Prevention / Early Detection
- Molecular Diagnostics Management
- Drug Access / Management

Enhanced Care Coordination

Ensuring optimal connectivity of all related care resources

- Transitions of Care
- Palliative/Compassionate Care
- Post-Acute Care
- Shared Decision Making (Patient Family Support)
- Cancer Network Design
- Community Agency Alignment

Investigative Medicine & Analytics

Participating in studies to further cancer care, provide medical policy feedback and determine endorsement

- NGS / broad panel sequencing
- COTA big data analytics
- eviCore
- Magellan
- Precision Medicine (NGS and cell free DNA, Proton Therapy with RWJ & UPenn, Rutgers Research Study on Brain Metastases)

Provider partnerships serve as a foundational element for strategy enablement.

Proprietary and Confidential HCM&T: Healthcare Delivery

Lung Cancer Bundle – Model Overview

Bundles

- Categorized in 2 types:
 - Chemotherapy
 - Immuno/Targeted

Design

 Each episode type is based on disease progression and therapeutic options

Financial Model

 Risk based bundle cancer specific

Patient Identification:

- The oncology value-based partner assigns the members into the program ("Assigned" Member)
- If a member moves into a different episode type, a new episode type is initiated and the costs for prior episode are adjusted

Duration:

• The case rate model pays at the time of service and reconciles annually, post the runoff period (larger case rate payments may be paid in 2-3 payments)

Colon, Prostate and Rectal Bundles - Model Overview

Bundles

 Categorized in 3 types

Design

 Each episode type is based on disease progression and therapeutic options

Financial Model

 Risk based bundle cancer specific

Patient Identification:

- The oncology value-based partner assigns the members into the program ("Assigned" Member)
- If a member moves into a different episode type, a new episode type is initiated and the costs for prior episode are adjusted

Duration:

• The case rate model pays at the time of service and reconciles annually, post the runoff period (larger case rate payments may be paid in 2-3 payments)

Breast Cancer Bundles- Overview

Type

 Categorized in 6 Levels

Design

 Each model is based on Disease progression and therapeutic options

Financial Model

 Risk based bundle cancer specific

Patient Identification:

- The oncology value based partner assigns the members into the program
- If a member moves into a different level +/- the costs are adjusted

Duration:

• The case rate model pays at the time of service and reconciles annually, post the runoff period. Larger case rate payments may be paid in two or three payments.

Other Bundle Opportunities

- Prostate (Metastatic) 1 Episode
- Head and Neck Two Episodes
- Multiple Myeloma Three Episodes
- Lymphoma- Two Episodes
- Esophageal Two Episodes

HORIZON BLUE CROSS BLUE SHIELD NEW JERSEY

Community Chimeric Antigen Receptor (CAR) T-Cell Therapy Pilot



Chimeric Antigen Receptor (CAR) T-Cell Therapy Background

CAR T-cell therapy is a cell-based gene therapy in which T-cells are collected and genetically engineered to express a chimeric antigen receptor that binds to a certain protein on a individuals cancerous cells. The CAR T-cells are then administered to the member to attack cancerous cells. The member is observed for potential serious side effects that may require medical intervention when present .

CAR - T Pilot Overview

Community Risk Pilot

- Amerisource Bergen
- Oncology Provider

Design

- Outpatient services for Apheresis/Chemo
- Community based program

Financial Model

- Fixed admin fees
- Home monitoring
- Case rate paid with oncologist/pharma at risk.
- Pharma/Provider/Emplo yer/Horizon.

Patient Identification:

• The oncologist attributes the member's with B-cell ALL, diffuse large B-cell (DLBCL and primary mediastinal large B cell lymphoma.

Duration:

• The case rate model pays at the time of service (6month period) and reconciles annually.